4
Nov 5 (Reuters) – T-Therapeutics: * T-THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $133 MILLION SERIES B FINANCING TO ACHIEVE CLINICAL PROOF-OF-CONCEPT FOR FIRST-IN-CLASS TCR BISPECIFIC THERAPIES IN CANCER
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)